VENTANA PD-L1 (SP263) Assay

PD-L1 predictive assay | Guiding immunotherapy 

A new option for identifying NSCLC patients most likely to benefit from OPDIVO® (nivolumab).
CE marked. 

Non-small cell lung cancer

Empowering pathologists to answer
PD-L1 questions

Using an approved assay to determine PD-L1 status for immunotherapy options is important. The VENTANA PD-L1 (SP263) Assay is optimized for use on VENTANA BenchMark instruments.


PD-L1 analytic assay

VENTANA analytic assays evaluate for expression of PD-L1 in tumor and immune cells in the context of the tumor microenvironment.

Rabbit Monoclonal Primary Antibody


The PD-L1 immunologic checkpoint

> Learn more

The tumor microenvironment